This post was originally published on this site The sandwich generation is one of the many terms that define caregiving. As you can guess, the term has nothing to do with two pieces of bread spread with peanut butter and jelly. Rather, the sandwich generation refers to those who currently are raising children or supporting…
Conditions
Conditions
Prestige’s HD201, a Biosimilar to Herceptin, Accepted for Review in Europe for HER2-positive BC
This post was originally published on this site The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) submitted by Prestige BioPharma for HD201, its lead biosimilar to Genentech‘s Herceptin (trastuzumab). Like Herceptin, HD201 is indicated for the treatment of women with HER2-positive breast cancer. Prestige’s lead biosimilar candidate also is indicated…
CAR T-Cell Candidate bb2121 Shows Promising Signs of Safety and Efficacy for Relapsed or Refractory Myeloma, Interim Data Show
This post was originally published on this site The candidate CAR-T cell therapy bb2121 showed a favorable safety profile and eliminated traces of cancer in nearly half of heavily pre-treated multiple myeloma patients included in a Phase 1 clinical trial, interim results show. The study, “Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple…
OncBioMune’s Experimental Chemo Shows Potential to Inhibit Growth of Drug-resistant OC Cells
This post was originally published on this site PGT, an experimental chemotherapy developed by OncBioMune, inhibited the growth of ovarian cancer cells resistant to multiple chemotherapeutic agents. These preliminary results suggest that the therapy could potentially be used to treat tumors that do not respond to standard chemotherapy. PGT is a combination of paclitaxel, gallium,…
American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer
This post was originally published on this site Funded by a $380,000 grant from the National Cancer Institute, researchers at the University at Buffalo (UB) in New York and Moscow State University in Russia are collaborating to study a potential biomarker for metastatic prostate cancer, and determine how to best detect it. While some prostate…
Virtual Reality May Improve Quality of Life of Hospitalized Dementia Patients, Study Says
This post was originally published on this site Virtual reality may help improve the quality of life for people with dementia, including those with Alzheimer’s disease, by stimulating them to recall past memories, reduce aggressive behavior, and connect with caregivers, a study suggests. The study, “Bring the Outside In: Providing Accessible Experiences Through VR for…
Chemo Resistance in TNBC Due to Molecular Changes That May Be Treatable, Study Suggests
This post was originally published on this site Triple-negative breast cancer (TNBC) cells can become resistant to chemotherapy by temporarily turning on molecular pathways that protect the tumor, new research using mouse models and patient tumor samples uncovered. Since one of these pathways is a metabolic process possible to target, the study may offer new…
The Existential Clarity that Comes with Traveling with Cancer
This post was originally published on this site “Hi there … I’m loving your travel pics. I really wish I was able to travel while going through treatment! How do you do it?” The little red notification glared back at me from my Instagram inbox, demanding my attention. It was a message from one of…
Pulmonary Hypertension Therapies May Help Heart Conditions in Certain Sarcoidosis Patients, Study Suggests
This post was originally published on this site While there no therapies approved for sarcoidosis-associated pulmonary hypertension (SAPH), pulmonary hypertension-specific therapies may help ease right heart dysfunction in a select group of patients, according to results of a large cohort study. The study, “Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension,” was published…
Phase 1/2 Trial of Immunotherapy AGI-134 to Open to US Patients with Solid Tumors
This post was originally published on this site BioLineRx is expanding the Phase 1/2 clinical trial of its investigational AGI-134 to include the U.S., now that regulatory officials there have approved the company’s request to test the treatment. The new sites are expected to open by mid-2020. The U.S. Food and Drug Administration’s favorable decision regarding its Investigational…
Cancer Vaccine Shows Potential against iNHL in Early Results
This post was originally published on this site A new cancer vaccine still in clinical testing showed potential for driving disease remission in patients with advanced indolent non-Hodgkin’s lymphoma (iNHL) and may help restore efficacy of immunotherapies, including checkpoint blockade therapies. The vaccine, administered directly to tumor lesions, was able to control or even shrink…
FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) of Darzalex (daratumumab) in combination with standard pre-transplant therapy for the treatment of patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The sBLA…